Developer docs
API playgroundTry for free, no card

Search company profiles

DarwinHealth

Full company profile

uuid000e2oc

Namestring
DarwinHealth
Legal namestring
DarwinHealth
Websiteurl
darwinhealth.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

DarwinHealth is a privately held precision cancer medicine company headquartered in New York City, founded in 2015 on systems biology research conducted at Columbia University by co-founders Andrea Califano (Chief Scientific Advisor) and Gideon Bosker (CEO). The company has developed a proprietary algorithmic platform branded as Oncotecture™, which analyzes tumor architecture and master regulator dependencies to identify tumor checkpoints, diagnostic biomarkers, and optimal drug combinations. DarwinHealth positions its methodology as going beyond genomic analysis to capture the systems-level biology of individual tumors.

The company's commercial offering is organized around four core products: Darwin OncoDiscovery (tumor checkpoint and biomarker identification), Darwin OncoTarget (therapeutic target identification), Darwin OncoTreat (drug combination matching for individual patients), and Darwin OncoSphere (diagnostic biomarker analysis). These products serve two primary customer segments: pharmaceutical companies seeking to prioritize and optimize developmental compound pipelines, and healthcare institutions seeking precision patient-drug matching for cancer treatment. The platform is positioned both as a clinical decision support tool and as a drug discovery engine, with DarwinHealth retaining the option to in-license or acquire under-valued compounds surfaced by its own algorithms.

DarwinHealth distributes its technology through a direct enterprise sales model targeting pharmaceutical and healthcare clients, supported by a Scientific and Medical Advisory Board of international experts. Scientific validation has been published in high-impact journals including Cell, Science, Nature Genetics, and Nature Communications Biology. Pricing is not publicly disclosed. The company holds registered trademarks for its core product brands and Oncotecture name. As of available data, DarwinHealth operates with 1-10 employees, has not disclosed institutional funding rounds, and reports no revenue figures.

Short descriptiontext

DarwinHealth is a private, New York-based precision cancer medicine company that applies proprietary Oncotecture™ systems biology algorithms to match individual cancer patients with optimal drugs and to help pharmaceutical companies prioritize developmental compound pipelines.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology software, cancer biomarker discovery, systems biology platform, drug combination matching, pharma pipeline optimization
Industry2 codes
1HLAAALAO
CodeHLAAALAOPrimaryYes
2HLAAALAL
CodeHLAAALALPrimaryNo
SIC code1 code
  • 2835
Product category
Precision Oncology Software
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Partnership Services
TypeSubscription Recurring
Description

DarwinHealth provides pharmaceutical companies with its algorithmic platform to optimize developmental compound pipelines and prioritize effective compounds for acquisition, in-licensing, and clinical development.

darwinhealth.com
2Clinical Decision Support
TypeSubscription Recurring
Description

The company matches individual cancer patients with optimal drugs and drug combinations, providing services to healthcare institutions for precision treatment decisions.

darwinhealth.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1Darwin OncoDiscovery
Description

Product for cancer patient matching and biomarker identification

darwinhealth.com
+2 more records
Core offering1 text field

DarwinHealth develops and licenses proprietary algorithmic platforms — Darwin OncoDiscovery, Darwin OncoTarget, Darwin OncoTreat, and Darwin OncoSphere — built on its Oncotecture™ systems-biology framework to identify tumor checkpoints, diagnostic biomarkers, and optimal drug combinations for individual cancer patients. The company also sells these capabilities to pharmaceutical companies for prioritizing developmental compounds and identifying under-valued assets for acquisition or in-licensing.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

DarwinHealth is a precision-focused cancer medicine company offering a suite of integrated products powered by proprietary algorithms and Oncotecture™-driven systems biology technologies. The product portfolio includes Darwin OncoDiscovery (diagnostic biomarkers and tumor checkpoint identification), Darwin OncoTargeet (therapeutic target identification), Darwin OncoTreat (drug combination optimization), and Darwin OncoSphere (biomarker analysis platform). These products collectively enable matching individual cancer patients at every disease stage with optimally suited drugs and drug combinations, while also providing pharmaceutical companies with pipeline optimization capabilities.

Product and service4 records
1Darwin OncoDiscovery
CategoryPrecision oncology software / biomarker discovery
Description

Proprietary systems-biology-driven platform for identifying and elucidating tumor checkpoints and diagnostic biomarkers to advance precision cancer medicine; sold to pharmaceutical R&D and cancer research organizations.

2Darwin OncoTarget
CategoryPrecision oncology software / therapeutic target identification
Description

Technology platform focused on identifying therapeutic targets in cancer using systems-biology approaches; serves pharmaceutical R&D and translational medicine teams.

3Darwin OncoTreat
CategoryPrecision oncology software / patient-drug matching
Description

Platform designed to identify outcome-optimizing drug combinations for individual cancer patients based on proprietary matching algorithms; supports clinical decision-making in healthcare institutions.

4Darwin OncoSphere
CategoryPrecision oncology software / comprehensive cancer analysis
Description

Product offering focused on diagnostic biomarker identification and tumor analysis using the Oncotecture™-driven technology platform.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Columbia University
Strategic tierCoreTypeStrategic or Co-development Partner
Description

DarwinHealth was founded based on research conducted at Columbia University. The company's technology and scientific leadership maintain close ties to academic research institutions, with co-founder Professor Andrea Califano serving as a faculty member at Columbia University.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DarwinHealth

Precision Oncology Softwaredarwinhealth.com

DarwinHealth is a private, New York-based precision cancer medicine company that applies proprietary Oncotecture™ systems biology algorithms to match individual cancer patients with optimal drugs and to help pharmaceutical companies prioritize developmental compound pipelines.

What DarwinHealth does

DarwinHealth is a privately held precision cancer medicine company headquartered in New York City, founded in 2015 on systems biology research conducted at Columbia University by co-founders Andrea Califano (Chief Scientific Advisor) and Gideon Bosker (CEO). The company has developed a proprietary algorithmic platform branded as Oncotecture™, which analyzes tumor architecture and master regulator dependencies to identify tumor checkpoints, diagnostic biomarkers, and optimal drug combinations. DarwinHealth positions its methodology as going beyond genomic analysis to capture the systems-level biology of individual tumors.

The company's commercial offering is organized around four core products: Darwin OncoDiscovery (tumor checkpoint and biomarker identification), Darwin OncoTarget (therapeutic target identification), Darwin OncoTreat (drug combination matching for individual patients), and Darwin OncoSphere (diagnostic biomarker analysis). These products serve two primary customer segments: pharmaceutical companies seeking to prioritize and optimize developmental compound pipelines, and healthcare institutions seeking precision patient-drug matching for cancer treatment. The platform is positioned both as a clinical decision support tool and as a drug discovery engine, with DarwinHealth retaining the option to in-license or acquire under-valued compounds surfaced by its own algorithms.

DarwinHealth distributes its technology through a direct enterprise sales model targeting pharmaceutical and healthcare clients, supported by a Scientific and Medical Advisory Board of international experts. Scientific validation has been published in high-impact journals including Cell, Science, Nature Genetics, and Nature Communications Biology. Pricing is not publicly disclosed. The company holds registered trademarks for its core product brands and Oncotecture name. As of available data, DarwinHealth operates with 1-10 employees, has not disclosed institutional funding rounds, and reports no revenue figures.

DarwinHealth firmographics

Firmographics
Name
DarwinHealth
Legal name
DarwinHealth
Website
https://darwinhealth.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
DarwinHealth is a private, New York-based precision cancer medicine company that applies proprietary Oncotecture™ systems biology algorithms to match individual cancer patients with optimal drugs and to help pharmaceutical companies prioritize developmental compound pipelines.
Ownership category
akta.pro rank

Where DarwinHealth is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

DarwinHealth business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Partnership Services: DarwinHealth provides pharmaceutical companies with its algorithmic platform to optimize developmental compound pipelines and prioritize effective compounds for acquisition, in-licensing, and clinical development.
  2. Clinical Decision Support: The company matches individual cancer patients with optimal drugs and drug combinations, providing services to healthcare institutions for precision treatment decisions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

DarwinHealth product offering

Product offering

Core offering

DarwinHealth develops and licenses proprietary algorithmic platforms — Darwin OncoDiscovery, Darwin OncoTarget, Darwin OncoTreat, and Darwin OncoSphere — built on its Oncotecture™ systems-biology framework to identify tumor checkpoints, diagnostic biomarkers, and optimal drug combinations for individual cancer patients. The company also sells these capabilities to pharmaceutical companies for prioritizing developmental compounds and identifying under-valued assets for acquisition or in-licensing.

Product overview

DarwinHealth is a precision-focused cancer medicine company offering a suite of integrated products powered by proprietary algorithms and Oncotecture™-driven systems biology technologies. The product portfolio includes Darwin OncoDiscovery (diagnostic biomarkers and tumor checkpoint identification), Darwin OncoTargeet (therapeutic target identification), Darwin OncoTreat (drug combination optimization), and Darwin OncoSphere (biomarker analysis platform). These products collectively enable matching individual cancer patients at every disease stage with optimally suited drugs and drug combinations, while also providing pharmaceutical companies with pipeline optimization capabilities.

Differentiator

Problem solved

Functional benefit

Brands

  • Darwin OncoDiscovery: Product for cancer patient matching and biomarker identification
  • Darwin OncoTargeet
  • Darwin OncoTreat

Products and services

  • Darwin OncoDiscovery Proprietary systems-biology-driven platform for identifying and elucidating tumor checkpoints and diagnostic biomarkers to advance precision cancer medicine; sold to pharmaceutical R&D and cancer research organizations.
  • Darwin OncoTarget Technology platform focused on identifying therapeutic targets in cancer using systems-biology approaches; serves pharmaceutical R&D and translational medicine teams.
  • Darwin OncoTreat Platform designed to identify outcome-optimizing drug combinations for individual cancer patients based on proprietary matching algorithms; supports clinical decision-making in healthcare institutions.
  • Darwin OncoSphere Product offering focused on diagnostic biomarker identification and tumor analysis using the Oncotecture™-driven technology platform.

Companies that use DarwinHealth

Customer profile

Segments2 records

Ideal customer profiles2 records

DarwinHealth technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature7 records

DarwinHealth partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Columbia UniversitycoreStrategic or Co-development PartnerDarwinHealth was founded based on research conducted at Columbia University. The company's technology and scientific leadership maintain close ties to academic research institutions, with co-founder Professor Andrea Califano serving as a faculty member at Columbia University.

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

DarwinHealth competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks4 records

Key highlights6 records

Customer concentration

DarwinHealth social profiles

Digital presence

DarwinHealth financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DarwinHealth leadership team

Management profile

Number of profiles

Profiles8 records

DarwinHealth funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DarwinHealth M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DarwinHealth

What does DarwinHealth do?

DarwinHealth develops and licenses proprietary algorithmic platforms — Darwin OncoDiscovery, Darwin OncoTarget, Darwin OncoTreat, and Darwin OncoSphere — built on its Oncotecture™ systems-biology framework to identify tumor checkpoints, diagnostic biomarkers, and optimal drug combinations for individual cancer patients. The company also sells these capabilities to pharmaceutical companies for prioritizing developmental compounds and identifying under-valued assets for acquisition or in-licensing.

Is DarwinHealth a public or private company?

DarwinHealth is a private company. It is classified as unknown and is currently operating.

When was DarwinHealth founded?

DarwinHealth was founded in 2017. It employs 1 to 10 people.

Where is DarwinHealth based?

DarwinHealth is headquartered in New York, United States, in the North America region.

How does DarwinHealth make money?

Two revenue lines are on record. Pharmaceutical Partnership Services are the primary driver. The others are clinical Decision Support.

Does DarwinHealth have an API?

No public API is recorded for DarwinHealth.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR Newswire APACDarwinHealth Introduces Quantum Cancer Biology: A Cell-State Systems Biology Framework for Precision OncologyDarwinHealth announced on Aug. 26, 2026 the release of "Quantum Cancer Biology," a cell-state systems biology framework combining single-cell transcriptomics, regulatory network inference and AI to target co-existing malignant cell states in resistant cancers. The company's Nature Genetics perspective, led by Dr. Andrea Califano and Dr. Kenneth P. Olive, identified six conserved pancreatic cancer cell states. The framework is being extended to glioblastoma and other aggressive solid tumors.AijournDarwinHealth Introduces Quantum Cancer Biology: A Cell-State Systems Biology Framework for Precision OncologyDarwinHealth announced on Aug. 26, 2026 its "Quantum Cancer Biology" framework, a cell-state systems biology approach combining single-cell transcriptomics, regulatory network inference and AI to target co-existing malignant cell states in resistant cancers. The company's Nature Genetics perspective, led by Dr. Pasquale Laise and Dr. Andrea Califano, identified six conserved pancreatic cancer cell states and their master regulator proteins. The framework is being extended to glioblastoma and other aggressive solid tumors.PR NewswireDarwinHealth Introduces Quantum Cancer Biology: A Cell-State Systems Biology Framework for Precision OncologyDarwinHealth announced Quantum Cancer Biology, a cell-state systems biology framework for precision oncology, based on a Nature Genetics study. The framework identifies multiple co-existing malignant cell states in resistant tumors, proposing multi-drug combinations to target them. It aims to develop more effective therapies for cancers with high mortality rates.NewswireDarwinHealth Introduces Quantum Cancer Biology: A Cell-State Systems Biology Framework for Precision OncologyDarwinHealth announced Quantum Cancer Biology, a cell-state systems biology framework for precision oncology, published in Nature Genetics. The framework uses single-cell transcriptomics and AI to decode multiple co-existing malignant cell states in resistant cancers like pancreatic cancer and glioblastoma. It aims to enable multi-drug combination therapies targeting all cellular states.PR NewswireDarwinHealth publica resultados de nova tecnologia viral baseada em checkpoints para prever medicamentos que inibem replicação do SARS-CoV-2: colaboração global destaca generalização do modelo ViroTreDarwinHealth published a paper in Communications Biology presenting ViroTreat, a network-based computational model that identifies antiviral drugs by targeting the host cell's transcriptional response to viral infection, achieving 83% accuracy (15 of 18 predicted drugs significantly reduced SARS-CoV-2 replication). The model was developed through a multi-institutional collaboration with researchers from Columbia University and the University of Florida in the USA, the University of Heidelberg in Germany, and the University of Bern in Switzerland. The company claims the approach represents a new paradigm in host-directed antiviral therapy and can be generalized to other viruses including influenza and emerging pathogens.PR NewswireDarwinHealth publica resultados de una tecnología para predecir medicamentos que inhiben la replicación del SARS-CoV-2: se destaca la generalizabilidad del modelo ViroTreat, el rol de las proteínas reDarwinHealth published research findings in Communications Biology on July 19, 2022, presenting ViroTreat, a network-based model for identifying antiviral drugs that target host cell responses to viral infection. The model achieved an 83% success rate, with 15 of 18 predicted drugs showing significant reduction in SARS-CoV-2 replication without affecting cell viability. The approach, developed through international collaboration with universities in the United States, Germany, and Switzerland, is designed to be generalizable to other viral pathogens including influenza.PR NewswireDarwinHealth publie les résultats d'une nouvelle technologie qui s'appuie sur des points de contrôle viraux pour prédire les médicaments qui inhibent la réplication du SRAS-CoV-2 : Le projet de collabDarwinHealth published a paper in Communications Biology on July 19, 2022, presenting ViroTreat, a network-based computational-experimental model for identifying antiviral drugs by targeting host cell transcriptional programs hijacked during viral infection. The model demonstrated an 83% success rate, with 15 of 18 predicted drugs showing significant SARS-CoV-2 replication reduction without affecting cell viability, outperforming negative control predictions. The research represents a potential new paradigm for host-directed antiviral therapy applicable across multiple pathogens, including coronaviruses and influenza.PR NewswireDarwinHealth Publishes Results of Novel, Viral Checkpoint-based Technology for Predicting Drugs that Inhibit SARS-CoV-2 Replication: Global Collaboration Highlights Generalizability of Reported ViroTrDarwinHealth announced the July 19, 2022 publication in Communications Biology (Nature Portfolio) of a foundational paper introducing ViroTreat, a novel regulatory network-based model for identifying antiviral drugs that target host cell responses to viral infection. The model achieved an 83% success rate in validation studies, correctly predicting 15 of 18 drugs as effective inhibitors of SARS-CoV-2 replication without affecting cell viability. The research, conducted through an international collaboration involving Columbia University, University of Florida, Heidelberg University, and University of Bern, represents a potentially generalizable approach to host-directed antiviral therapy applicable to a broad spectrum of viral pathogens, including future pandemic threats.PR NewswireDarwinHealth anuncia una colaboración de investigación con Bristol Myers Squibb en una iniciativa de novedosos descubrimientos de para identificar blancos de cáncer (NCTI)DarwinHealth, a New York-based biotechnology company, announced a research collaboration with Bristol-Myers Squibb Company in the Novel Cancer Target Initiative (NCTI) to identify new cancer targets across multiple tumor subtypes using proprietary quantitative systems biology algorithms and databases. The initiative will leverage DarwinHealth's master regulator analysis to discover recurring targets applicable across different cancer types for multi-indication drug development by Bristol Myers Squibb. As part of the collaboration, DarwinHealth will receive an upfront payment and potential development and commercialization milestone payments, building on an existing Compound-2-Clinic collaboration initiated with Celgene in August 2019.PR NewswireDarwinHealth Announces a Research Collaboration with Bristol Myers Squibb for a Novel Cancer Target Discovery (NCTI) InitiativeDarwinHealth, a New York City-based biotechnology company, announced a scientific research collaboration with Bristol Myers Squibb called the Novel Cancer Target Initiative (NCTI), which employs quantitative systems biology-based algorithms to identify novel cancer targets across a range of tumor subtypes. As part of the agreement, DarwinHealth will provide proprietary drug databases and tumor context-specific analyses of Master Regulators, receiving an upfront payment and potential development and commercialization milestone payments. The NCTI extends an existing Compound-2-Clinic collaboration that Bristol Myers Squibb inherited through its acquisition of Celgene in 2019.